Biodexa Pharmaceuticals Plc
BDRX
$1.55
-$0.01-0.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -61.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -61.97% |
| Cost of Revenue | 84.40% | 83.83% | -1.99% | 1.55% | -28.81% |
| Gross Profit | -93.24% | -92.63% | -12.96% | -17.05% | 25.71% |
| SG&A Expenses | 144.74% | 143.98% | -10.53% | -7.28% | -80.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -128.74% | -126.97% | -- | -- | -148.57% |
| Total Operating Expenses | 101.74% | 101.11% | -6.30% | -2.90% | -60.13% |
| Operating Income | -108.54% | -107.90% | -0.28% | -3.91% | 60.06% |
| Income Before Tax | 27.67% | 27.89% | 10.27% | 7.03% | 24.60% |
| Income Tax Expenses | -9.14% | -8.84% | 56.27% | 54.66% | 74.79% |
| Earnings from Continuing Operations | 28.91% | 29.13% | 6.56% | 3.18% | 19.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.91% | 29.13% | 6.56% | 3.18% | 19.19% |
| EBIT | -108.54% | -107.90% | -0.28% | -3.91% | 60.06% |
| EBITDA | -112.54% | -111.88% | -0.39% | -4.03% | 60.74% |
| EPS Basic | 94.29% | 94.30% | -- | -- | -- |
| Normalized Basic EPS | 90.90% | 90.93% | -- | -- | -- |
| EPS Diluted | 94.29% | 94.30% | -- | -- | -- |
| Normalized Diluted EPS | 90.90% | 90.93% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,142.96% | 1,142.96% | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |